Calendario›VYGR›VY7523
VY7523
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Ensayo de Voyager Therapeutics, Inc. en Alzheimer's Disease (AD) (del registro, en inglés).
- Fase
- Fase 1/2
- Estado
- En marcha, sin reclutar
- Participantes
- 52
- Centros
- 23
- Fin del objetivo primario
- may 2027
previstos
estimado por el promotor
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en mar 2025.
Qué mide
Characterization of the safety and tolerability of VY7523 in participants with early AD (Cohorts 1 and 2: up to 6 months Cohort 3: up to 12 months) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.
Más ensayos de VYGR
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| VY1706 Low dose | Fase 1 | Reclutando pacientes | abr 2029 (prevista) |
| Intraparenchymal rAAV1 | Fase 1 | Retirado antes de empezar | dic 2024 (prevista, ya pasada: sin actualizar en el registro) |
Todos los de VYGR, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06874621), actualizada en nov 2025.